Project Grant R01AI183396
Award Date 9/9/25
Completion Date 8/31/30
Dollars Obligated $134K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Argentina
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $123,280 project grant under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) to Instituto De Biologia Molecular Y Celular De Rosario (IBR) in Argentina. The grant aims to investigate the adaptive immune response against Trypanosoma cruzi, the parasite that causes Chagas disease, with the goal of developing effective vaccine candidates. The research will focus on enhancing CD8+ T cell...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $133,800 to the Fundacion Instituto De Investigaciones Biotecnologicas in Argentina. The funding supports research to fully understand protein trafficking through the contractile vacuole complex (CVC) in the parasite Trypanosoma cruzi, the causative agent of Chagas disease. The research aims to...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is providing $133,693 to the Fundacion Instituto De Investigaciones Biotecnologicas in Argentina to study the role of an unusual variant nucleosome in the life cycle of the Toxoplasma gondii parasite. The research aims to investigate how epigenetic changes in T. gondii's unique H2A.Z/H2B.Z double-variant nucleosome...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $160,500 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Baylor College of Medicine to develop and validate a highly sensitive serological assay for detecting all geographic variances of Trypanosoma cruzi infection, which causes Chagas disease. This 2-year project aims to address the limitations of current Chagas diagnostic tests and reduce the burden on the healthcare system...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, will support the development of a panel of antibodies to detect markers of Trypanosoma cruzi infection, the causative agent of Chagas disease. The $449,408 award to Duke University, with a performance period from Jul 1, 2025 to Jun 30, 2027, aims to generate antibodies that can effectively diagnose acute and chronic Chagas...
- This $412,581 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research to define the roles of specialized mitochondrial DNA polymerases (POLIB and POLID) in the replication and maintenance of the complex kinetoplast DNA network of African trypanosomes. These parasites cause neglected tropical diseases such as human African trypanosomiasis, Chagas disease,...
- This federal Project Grant award of $107,699 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to strengthen administrative and financial oversight of NIAID grants at the Instituto de Efectividad Clinica y Sanitaria (IECS) and other research institutions in South America. The primary objectives are to: 1) Build IECS' capacity to properly manage NIAID/NIH grants in accordance with regulations,...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,000,000 Project Grant to Partillion Bioscience Corp, a biotechnology company based in Los Angeles, California. The grant, funded under NIAID's Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of advanced workflows utilizing Partillion's specialized hydrogel microparticle technology called "nanovials". The goal is to enable ultra high-throughput screening and functional...
- The University of Cincinnati was awarded a $444,688 Project Grant by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant will fund research to characterize cyclic AMP (cAMP) signaling microdomains in the human pathogen Trypanosoma cruzi, which causes Chagas disease - a leading cause of disability and premature death in the Americas. Specifically, the research aims to study the role of cAMP in the...
- This $451,000.00 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) federal grant program, supports research to investigate the manipulation of antibody responses by a retrovirus. The research aims to enhance understanding of how pathogens can directly or indirectly modulate B cells, which play a critical role in providing long-term protective immunity. Specifically, the study will examine...